[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100289539":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":42,"studyPopulation":43,"armGroups":44,"interventions":50,"overallOfficials":55,"centralContacts":61,"locations":70,"responsibleParty":87,"collaborators":15,"id":89,"slug":15,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":90,"sex":96,"minAge":15,"maxAge":15,"enrollmentInfo":97,"targetDuration":100,"studyType":101,"phases":15,"briefSummary":102,"conditions":103,"keywords":15,"overallStatus":72,"whyStopped":15,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"EBG MedAustron GmbH","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":15},[9,13,16,18,20,22],{"measure":10,"description":11,"timeFrame":12},"Therapy response","Therapy Response according to RECIST Version 1.1","10 years",{"measure":14,"description":15,"timeFrame":12},"Overall survival",null,{"measure":17,"description":15,"timeFrame":12},"Progression-free survival",{"measure":19,"description":15,"timeFrame":12},"Local progression-free survival",{"measure":21,"description":15,"timeFrame":12},"Cause-specific survival",{"measure":23,"description":24,"timeFrame":12},"Toxicity according to NCI CTCAE","Acute\u002Flate toxicity according to CTCAEv4.03, June 14,2010",[26,30,33,36],{"measure":27,"description":28,"timeFrame":29},"EORTC-QLQ-C30","Patient-reported quality of life","Through study completion, at 3, 5, and 10 years",{"measure":31,"description":32,"timeFrame":29},"EORTC-QLQ-BN20","Patient-reported quality of life for brain cancer patients",{"measure":34,"description":35,"timeFrame":29},"EORTC-QLQ-PR25","Patient-reported quality of life for prostate cancer patients",{"measure":37,"description":38,"timeFrame":29},"Neurocognitive test battery","Change in cognition from baseline to endpoint as measured by standardized subtests of test battery",{"allocation":15,"interventionModel":15,"interventionModelDescription":15,"primaryPurpose":15,"observationalModel":40,"timePerspective":41,"maskingInfo":15},"COHORT","PROSPECTIVE","During and up to 10 years after radiation therapy data regarding tumor control and treatment response as well as acute and late toxicities will be collected at regular time intervals. Additionally quality of life and sociodemographic status will be assessed in all study patients and neurocognitive assessment will be performed in patients undergoing ion radiation of the brain.","Patients treated with ion beam therapy at MedAustron",[45],{"label":46,"type":15,"description":47,"interventionNames":48},"Ion beam therapy","All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.",[49],"Radiation: Protons and Carbon Ions",[51],{"type":52,"name":53,"description":15,"armGroupLabels":54,"otherNames":15},"RADIATION","Protons and Carbon Ions",[46],[56,59],{"name":57,"affiliation":5,"role":58},"Yvonne Goy, MD","PRINCIPAL_INVESTIGATOR",{"name":60,"affiliation":5,"role":58},"Piero Fossati, MD MSc",[62,67],{"name":57,"role":63,"phone":64,"phoneExt":65,"email":66},"CONTACT","+43 2622 26 100","407","yvonne.goy@medaustron.at",{"name":60,"role":63,"phone":64,"phoneExt":68,"email":69},"408","piero.fossati@medaustron.at",[71],{"facility":5,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"RECRUITING","Wiener Neustadt","Lower Austria","2700","Austria","AT",{"type":79,"coordinates":80},"Point",[81,82],16.23196,47.80485,{"lat":82,"lon":81},[85,86],{"name":57,"role":63,"phone":64,"phoneExt":65,"email":66},{"name":60,"role":63,"phone":64,"phoneExt":68,"email":69},{"type":88,"investigatorFullName":15,"investigatorTitle":15,"investigatorAffiliation":15,"oldNameTitle":15,"oldOrganization":15},"SPONSOR","100289539",false,"NCT03049072","Ion Therapy Patient Registry","A Prospective Registry Study to Record Clinical Results and Side Effects of Ion Beam Therapy at MedAustron","REGI-MA-002015","Inclusion Criteria:\n\n* Patients with tumor disease treated with ion beam therapy at MedAustron\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Comorbidities endangering treatment delivery or study compliance","ALL",{"count":98,"type":99},2800,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of the study is the prospective and standardized data collection of patients treated with ion therapy at MedAustron.",[104],"Ion Beam Radiation Therapy for Tumor Patients","2026-03-19",{"date":107,"type":108},"2026-03-23","ACTUAL",{"date":110,"type":108},"2016-12",{"date":112,"type":99},"2036-12",{"name":5,"class":6},1]